BIOMAT Database Logo BIOMAT Database Logo

Vasodilator therapy for pulmonary hypertension. 1980

S Rich

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006830 Hydralazine A direct-acting vasodilator that is used as an antihypertensive agent. Hydrallazin,Apresoline,Apressin,Apressoline,Hydralazine Hydrochloride,Hydralazine mono-Hydrochloride,Hydrazinophthalazine,Nepresol,Hydralazine mono Hydrochloride,Hydrochloride, Hydralazine,mono-Hydrochloride, Hydralazine

Related Publications

S Rich
Vasodilator therapy for pulmonary hypertension.
May 1980, The New England journal of medicine,
S Rich
Vasodilator therapy for pulmonary hypertension.
May 1980, The New England journal of medicine,
S Rich
Vasodilator therapy for primary pulmonary hypertension.
October 1984, Mayo Clinic proceedings,
S Rich
Vasodilator therapy for primary pulmonary hypertension.
January 1985, Annual review of medicine,
S Rich
Pulmonary hypertension--beyond vasodilator therapy.
January 1998, The New England journal of medicine,
S Rich
[Vasodilator therapy in pulmonary hypertension].
October 1986, Vnitrni lekarstvi,
S Rich
Vasodilator therapy for primary pulmonary hypertension in children.
March 1999, Circulation,
S Rich
Vasodilator therapy in primary pulmonary hypertension.
March 1981, Chest,
S Rich
Cardiovascular effects of vasodilator therapy for pulmonary arterial hypertension.
May 1983, Clinics in chest medicine,
S Rich
Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards.
August 1985, Annals of internal medicine,
Copied contents to your clipboard!